Hbk Investments L P Cellectis S.A. Transaction History

Hbk Investments L P

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$25.99 - $30.6 $868,819 - $1.02 Million	-33,429 Reduced 77.63%	9,633 $272,000
Q2 2018 Aug 14, 2018	BUY	$27.78 - $38.53 $136,788 - $189,721	4,924 Added 12.91%	43,062 $1.22 Million
Q1 2018 May 15, 2018	BUY	$27.78 - $35.19 $584,435 - $740,327	21,038 Added 123.03%	38,138 $1.2 Million
Q4 2017 Feb 14, 2018	BUY	$23.33 - $35.01 $398,942 - $598,671	17,100	17,100 $498,000

10.8M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $71M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Hbk Investments L P, based on Form 13F filings with the SEC.

Stay updated on Hbk Investments L P with notifications on news.